Sino Biopharmaceutical (HKG:1177) will take an additional 5% stake in its CT Tianqing subsidiary in a deal worth 4.48 billion yuan.
The acquisition will increase Sino Biopharm's indirect stake in CT Tianqing to 65% from 60%, according to a Friday filing on the Hong Kong bourse. Completion is expected Sept. 16, subject to the satisfaction or waiver of the transaction conditions.